Key facts
- This page summarizes Ryan H. Siurek's Form 4 filing for BIODESIX INC (BDSX).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 May 2023, 20:16.
Ryan H. Siurek - 08 May 2023 Form 4 Insider Report for BIODESIX INC (BDSX)
- Reporting relationship
- Chief Accounting Officer
- Issuer ticker
- BDSX
- Reported as of
- 08 May 2023
- Net transaction value
- -$3,170
- SEC form
- 4
- Accepted by SEC
- 10 May 2023, 20:16:23 UTC
- Prior SEC filing
- 03 Mar 2023
- Next SEC filing
- 18 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robin H. Cowie as Attorney-in-Fact for Ryan H. Siurek
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ryan H. Siurek filed Form 4 for BIODESIX INC (BDSX) on 10 May 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2023.
- Current net transaction value: -$3,170.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BDSX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,484
- Change %
- +15%
- Price
- Shares after
- 42,288
- Date
- 08 May 2023
- Ownership
- Direct
- Footnotes
- F1, F2
BDSX
transaction
Common Stock
Sale
- Transaction value
- $2,281
- Shares
- -1,456
- Change %
- -3.4%
- Price
- $1.57
- Shares after
- 40,832
- Date
- 09 May 2023
- Ownership
- Direct
- Footnotes
- F3, F4
BDSX
transaction
Common Stock
Sale
- Transaction value
- $889
- Shares
- -564
- Change %
- -1.4%
- Price
- $1.58
- Shares after
- 40,268
- Date
- 10 May 2023
- Ownership
- Direct
- Footnotes
- F3, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BDSX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,927
- Change %
- -8.3%
- Price
- $0.000000
- Shares after
- 21,193
- Date
- 08 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,927
- Exercise price
- Footnotes
- F1, F6
BDSX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,557
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 3,557
- Date
- 08 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,557
- Exercise price
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Includes 9,643 shares purchased under the Issuer's Employee Stock Purchase Plan on February 28, 2023.
Footnote F3
These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.
Footnote F4
The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.6039, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.5332 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F6
These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Footnote F7
These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.